Sun Pharmaceutical Industries Ltd.

Taro Pharmaceuticals (Canada), an indirect subsidiary of Sun Pharmaceutical Industries, has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals, a Canadian pharmaceutical corporation. Post the acquisition of Thallion Pharmaceutical, Taro Pharmaceuticals would have only rights for development of orphan drug candidate, Shigamab, which targets E. Coli-induced hemolytic-uremic syndrome.

Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.